Investor Presentaiton
2030
Addressing high unmet medical need in
Immunology, Cardiovascular & Neuroscience
Immunology
Cardiovascular
2023
Psoriasis $26B+
UC $7B+
PSA $5B+
$60B+
Pulmonary
Fibrosis $5B+
Lupus $2B+
Alopecia $0.6B+
EOE $40M+
SjS $19M+
Psoriasis $33B+
Stroke $1.8B+
ACS $0.5B+
HFPEF $8B+
$30B+
CD $16B+
AF $19B+
ACS $0.2B+ Stroke $3B+
UC $10B+
HFPEF $5B+
Pulmonary
Fibrosis $2B+
HCM $5B+
$75B+
$21B+
CD $18B+
Alopecia $1B+
PSA $6B+
Lupus $5B+
SjS $0.4B+ EOE $0.4B+
ll Bristol Myers Squibb™
*CV markets impacted by generic entry in Atrial Fibrillation
Source: EvaluatePharma estimates; totals may not add due to rounding
AF $8B+
MS $23B+
Neuroscience
MS $21B+
ALS $1B+
Alzheimer's $1B+
$23B+
$38B+
Alzheimer's
$12B+
ALS $3B+
Not for Product Promotional Use
149View entire presentation